Bristol Myers Squibb Announces Results from Late-Stage Sclerosis Study

Bristol Myers Squibb has announced the outcomes of the late-stage medical study, which investigated the efficiency and risks of Zeposia for managing multiple sclerosis relapse.

Multiple sclerosis is a chronic autoimmune disease that affects the central nervous system, causing a range of symptoms due to damage to the myelin sheath surrounding nerve fibers.

Based on the results, Zeposia demonstrated that it remains both safe and effective, showing an exceptionally low yearly relapse rate of 0.098.

Notably, all reported safety issues were consistent with Zeposia’s established safety record and did not raise any new issues.

Jonathan Sadeh, head executive of the immunology, cardiovascular, and neuroscience development programme, stated, “Currently, no cure exists for multiple sclerosis, but effective strategies and treatments can help slow disease progression and alleviate symptoms.”

Sadeh went on to add, “These DAYBREAK efficacy, safety, and rebound data underscore a consistent and sustained safety and efficacy profile and add to the body of evidence supporting Zeposia’s role in the treatment armamentarium.”

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.